Safety and Efficacy of Superselective Y90 with Resin in 3 Cm or Smaller Liver Lesions

Monday, April 13, 2026

4:21 PM - 4:30 PM ET

Location: 701A

Presenting Author(s)

Asad Baig, MD

Assistant Professor Interventional Radiology, Director of Research
Columbia University, New York, United States

Author/Co-author(s)

RA

Riyaz Abidi, BS

Student
Rowan Medical School, New York, United States
RS

Rhea Sakaria, BS

Student
Sophie Davis Medical School, New York, United States
Kiyon Naser-Tavakolian, MD

Assistant Professor Interventional Radiology
Columbia University, New York, United States
John Filtes, MD

IR/DR Resident
Columbia University Irving Medical Center, New York, United States
AS

Abin Sajan, MD

Resident Physician
Columbia University Medical Center, New York, United States
DH

David Hirschl, M.D.

Inverventional Radiologist
Montefiore Medical Center, New York, United States
Stephen P. Reis, MD, FSIR, MBA

Associate Professor Interventional Radiology
Columbia University, New York, United States
NA

Noor Ahmad, MD

Associate Professor Interventional Radiology
Columbia University, New York, United States

Purpose: There is limited data on superselective tumor coverage (STC) radioembolization for treatment of liver lesions using yttrium 90 (y90) resin microsphere doses determined by using a single-compartment medical internal radiation dosimetry (MIRD) model. The newer dosing options for resin include 6, and 7 day pre-calibrated doses, which have less spheres and higher GBq activity per sphere. Our purpose is to evaluate the efficacy and safety of STC treatment of liver lesions 3 cm or smaller with y90 resin microspheres using a single-compartment MIRD model and evaluate response on follow up imaging based on Modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria

Materials and Methods: This retrospective single-center study included 13 liver lesions 3 cm or smaller in 9 adults who underwent STC with y90 resin microspheres. 12 lesions were HCC and 1 lesion was mCRC. 6 and 7 day precalibrated y90 STC doses between January 2025 and July 2025 were included and posttreatment SPECT/CT or PET/CT were performed. Adverse events were assessed using the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Per-lesion response rates were assessed at imaging using mRECIST

Results: Among 13 liver lesions, 12 achieved complete response (92.3%) and 1 achieved partial response (7.7%) at 2-3 month follow up MRI. 7 patients had no adverse events and 2 had mild abdominal pain, classified as Grade 1 CTCAE. Dosing was calculated utilizing single compartment MIRD model at a range between 250-400 Gy with mean calculated dose 370 Gy. Liver toxicity, assessed through AST/ALT and bilirubin levels showed no significant increases post procedure. All grade 1 reported adverse events resolved within two weeks. 1 patient with 3 lesions was successfully bridged to transplant. Explant demonstrated complete pathologic necrosis

Conclusion: Our preliminary data suggests Y-90 STC radioembolization with 6 and 7 day resin dosing with MIRD model in 3 cm or smaller lesions is safe and effective without significant adverse effects